These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16609301)

  • 41. Asymmetric dimethylarginine and kidney disease--marker or mediator?
    Vallance P; Leiper J
    J Am Soc Nephrol; 2005 Aug; 16(8):2254-6. PubMed ID: 15987745
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.
    Mallamaci F; Zoccali C
    J Ren Nutr; 2009 Jan; 19(1):25-8. PubMed ID: 19121766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Asymmetric dimethylarginine: An crucial regulator in tissue fibrosis.
    Zhao WC; Li G; Huang CY; Jiang JL
    Eur J Pharmacol; 2019 Jul; 854():54-61. PubMed ID: 30951718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?
    Caplin B; Leiper J
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1343-53. PubMed ID: 22460557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel cardiovascular risk factors in end-stage renal disease.
    Zoccali C; Mallamaci F; Tripepi G
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S77-80. PubMed ID: 14684678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Asymmetric dimethylarginine and hypertension in cerebral small vessel disease.
    Tsuda K
    Stroke; 2007 Jul; 38(7):e48; author reply e49. PubMed ID: 17510451
    [No Abstract]   [Full Text] [Related]  

  • 47. Adiponectin in patients with chronic kidney disease.
    Adamczak M; Chudek J; Wiecek A
    Semin Dial; 2009; 22(4):391-5. PubMed ID: 19708988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardio-renal-anemia syndrome: a link between erythropoietin, dimethylarginine and homocysteine.
    Righetti M
    Curr Med Chem; 2012; 19(21):3502-7. PubMed ID: 22680636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal disease: the two faces of nitric oxide.
    Klahr S; Morrissey J
    Lab Invest; 1995 Jan; 72(1):1-3. PubMed ID: 7837782
    [No Abstract]   [Full Text] [Related]  

  • 50. Ageing as a determinant of renal and vascular disease: role of endothelial factors.
    Barton M
    Nephrol Dial Transplant; 2005 Mar; 20(3):485-90. PubMed ID: 15701673
    [No Abstract]   [Full Text] [Related]  

  • 51. Asymmetric dimethylarginine, an endogenous NO synthase inhibitor, in human breast milk.
    Tsukahara H; Nagasaka H
    Early Hum Dev; 2010 Feb; 86(2):69-70. PubMed ID: 20117887
    [No Abstract]   [Full Text] [Related]  

  • 52. L-arginine-nitric oxide pathway in end-stage renal disease.
    Prabhakar SS
    Am J Kidney Dis; 2002 Jan; 39(1):195-8; discussion 198-202. PubMed ID: 11774121
    [No Abstract]   [Full Text] [Related]  

  • 53. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.
    Wilcox CS
    Hypertension; 2012 Feb; 59(2):375-81. PubMed ID: 22215715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside.
    Hannemann J; Zummack J; Hillig J; Böger R
    Pulm Circ; 2020; 10(2):2045894020918846. PubMed ID: 32313644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Asymmetric Dimethylarginine (ADMA) in Pediatric Renal Diseases: From Pathophysiological Phenomenon to Clinical Biomarker and Beyond.
    Hsu CN; Tain YL
    Children (Basel); 2021 Sep; 8(10):. PubMed ID: 34682102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective.
    Zoccali C
    Kidney Int; 2006 Jul; 70(1):26-33. PubMed ID: 16723985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological interventions on asymmetric dimethylarginine, a clinical marker of vascular disease.
    Marín M; Máñez S
    Curr Med Chem; 2011; 18(5):714-24. PubMed ID: 21182486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nitric oxide in renal disease.
    Martin PY; Féraille E
    Adv Nephrol Necker Hosp; 1999; 29():93-113. PubMed ID: 10561739
    [No Abstract]   [Full Text] [Related]  

  • 59. L-arginine and arginine analogs in progressive renal failure.
    Sanders PW
    Blood Purif; 1995; 13(3-4):219-27. PubMed ID: 7619393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comment: the asymmetrical dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in the regulation of nitric oxide generation.
    Vallance P
    Clin Sci (Lond); 2001 Feb; 100(2):159-60. PubMed ID: 11171284
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.